Thank you, Henrik. I will now provide an update on our European commercialization strategy, followed by an overview of our next steps. Value drivers include geographic expansion for Pepaxti to the rest of the world and our pipeline progress. We have attracted many new shareholders following our rights issue, which is why I wish to reiterate some fundamental facts about our European commercialization strategy. It is grounded on Pepaxti being a fully approved drug for treating an incurable disease, providing an expanding market opportunity valued at 1.5 billion SEK. Currently, our focus is on increasing sales in markets where we have secured access, diversifying our revenue streams by opening new markets, and forming partnerships for our geographic expansion.
These efforts are now fully financed, enabling us to achieve our profitability target by the end of 2026. A short reminder of our business model, which is designed to allow for maximum cost-effectiveness, providing high returns due to high margins and low cost of sold goods. Now let's take a look at our launch progress in Europe. Our ambition remains to launch as fast as possible, with a price that reflects our innovation and provides value to both patients and shareholders. In our profitability plan, we have counted on sales from Germany, Austria, Spain, Italy, the Netherlands, and some in the Nordics. These are the different steps in the market access process, and let me remind you of that.
The timelines for the review and negotiation phases are country-specific and are largely controlled by payers. Our last quarterly update was held relatively recently, and due to our belated Q1 report, we have since encountered holiday periods in Europe. We have continued our dialogue with payers in Ireland, Norway, and Italy. We have one major development to report, which is that we have submitted a value dossier in France that is currently being reviewed by the payer. This review will conclude the cost-effectiveness and benefit assessment and takes approximately six months. France is in our third launch phase due to how difficult it is to gain a reasonable price in France, but given the size and potential of the market, and given the support and feedback we have gained from key experts on the unmet need for our medicine, we will do all we can to give French patients access to Pepaxti. As France is not part of our profitability plan, unlocking France ahead of 2026 would be an upside. In addition to Germany and Spain, the largest markets where we are currently selling, we also see sales in Greece and Austria, which is following the logic of other markets. Key opinion leader support and positive clinical experiences are generating demand as the multiple myeloma treatment landscape is rapidly evolving. In particular, more immunotherapies are being launched, focusing on earlier lines of treatment, which are starting to become crowded. Just recently, one big pharma company announced that they are shutting down the development of their bispecific for multiple myeloma, which is a sign that the competition in this space is fierce. Unmet medical need in later lines for other modes of action, however, remains due to immune exhaustion, which increases with successful treatments in earlier lines. The patient population in later lines is growing, and Pepaxti with its unique mode of action can take a strong position and make a big difference for these patients. Before we move to questions and answers, I would also like to talk about our next steps as value drivers. And we have some exciting developments both on our partnership side as well as pipeline progress. As I mentioned in the introduction, we have just recently signed an agreement with a World Orphan Drug Alliance partner covering Africa. This is a partner that is an expert in named patient sales in rare diseases and very well connected within the multiple myeloma community. Through our partnership with Red Pharma in Bihar, we have the potential to, on request, sell to Pakistan and the entire sub-Saharan Africa. But the focus and potential is in South Africa. We are working with named patient sales partnerships for a couple of reasons. First, we can expect to reach patients and see sales between 6 to 12 months. This may sound long, but it's far shorter than if we were to go for regulatory approval and regular market access. Secondly, the nature of named patient sales will tell us if it's worthwhile to invest in further commercialization, letting us test the market through these partnerships without jeopardizing our focus from our core revenue stream, which is Europe. In markets where we believe in a good return on investment to immediately go for regulatory approval, we are exploring other types of partnerships, and during the second quarter, we have advanced our discussions with partners and regulators in additional markets focusing on Japan, China, and South Korea, which we believe remain the most promising. And we hope to be able to share news on progress in some of those in the near future. Let me spend some time on our pipeline. As you know, we have two technology platforms: the SPiKE platform and the PDC platform. During the second quarter, we selected our first candidate drug, or SP1, from the SPiKE platform, which I wish to focus on now. Before I speak more about our construct, let's have a brief look at how natural killer cell engagement can differ from T cell therapy. Immunotherapy means that we are utilizing the immune system to fight cancer, and T cell therapies, clinically proven and launched across many different tumor types, are known to be very effective. But with the challenge and risk of severe side effects that need to be carefully monitored and managed. To put it simply, this is due to two powerful T cells.